| Breakdown ₩ m | 2026 Q2 |
|---|---|
| Total Revenue | 5 |
| Operating Income | 0 |
| Finance Income | 0 |
| Finance Costs | -0 |
| Pretax Income | 0 |
| Income Tax Expense | 0 |
| Net Income | 0 |
| Breakdown ₩ m | 2026 Q2 |
|---|---|
| Total Assets | 16 |
| Current Assets | 11 |
| Cash & Cash Equivalents | 5 |
| Non-current Assets | 6 |
| Property, Plant & Equipment | 1 |
| Intangible Assets | 1 |
| Total Liabilities | 7 |
| Current Liabilities | 6 |
| Non-current Liabilities | 0 |
| Total Equity | 10 |
| Share Capital | 0 |
| Retained Earnings | -21 |
| Breakdown ₩ m | 2026 Q2 |
|---|---|
| Not reported for this company. | |
| Symbol | Last Price |
|---|---|
| 185750Chong Kun Dang Pharmaceutical Corp. | ₩68,000 -0.3% |
| 115180Qurient Co., Ltd. | ₩23,050 +17.3% |
| 476830Rznomics, Inc. | ₩28,200 +6.8% |
| 003850Boryung Corporation | ₩9,040 +1.6% |
| 085660Chabiotech Co., Ltd. | ₩8,090 +2.1% |
| 476060Onconic Therapeutics, Inc. | ₩16,440 -3.9% |
| 041960Komipharm International Co., Ltd. | ₩9,710 +3.5% |
| 317450Myungin Pharm | ₩44,650 +0.0% |
| 001060JW Pharmaceutical | ₩27,500 +1.3% |
| 456160G2GBIO, Inc. | ₩37,950 +5.7% |